AISAP LTD

AISAP LTD develops FDA-cleared AI diagnostic software for point-of-care ultrasound (POCUS) systems, with a primary focus on cardiac imaging and structural heart disease detection. The company's flagship product, POCUS-OS™, is an all-in-one AI operating system that integrates with existing ultrasound devices from major manufacturers (GE, Philips, Siemens, Samsung, SonoSite, Butterfly, Wisonic, and others) to deliver expert-level cardiac measurements and automated diagnosis at the bedside. The platform includes AI-powered interpretation, structured reporting (reducing reporting time by up to 90%), cloud-based or on-premise PACS functionality, and seamless EMR integration. Clinical applications include early detection of aortic stenosis, mitral regurgitation, tricuspid regurgitation, right ventricular dysfunction, pericardial effusion, and pulmonary embolism risk assessment. The company serves hospitals, health systems, clinics, and emergency departments globally. Research partnerships include Stanford, Mayo Clinic, Inova, Jefferson Health, and others. AISAP emphasizes workflow efficiency, reduced length of stay, improved diagnostic accuracy for non-cardiologists, and increased billing capture (up to 95% billable encounters). The platform operates on flexible deployment (on-premise to cloud architecture) and includes QA/accreditation tools for quality standardization. FDA clearance status confirmed on website; CE and ISO compliance inferred from regulatory context but not explicitly stated.